Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Will the need for programmed cell death 1 ligand 1 (PD-L1) testing affect the use of checkpoint inhibitors in non–small-cell lung cancer? Yes.
Two agents, nivolumab and pembrolizumab, directed against the programmed cell death 1 (PD-1) immune checkpoint have been approved by the US Food and Drug Administration for treatment of previously treated non–small-cell lung cancer (NSCLC).1-3 Nivolumab is approved with no requirement for programmed cell death 1 ligand 1 (PD-L1) expression, whereas pembrolizumab is approved only in patients whose tumors express PD-L1. As a result of these differing approvals, substantial debate has arisen regarding the appropriate role of PD-L1 testing to select patients for therapy.
Lisberg A, Garon EB. The Value of PD-L1 Testing in Non–Small-Cell Lung Cancer. JAMA Oncol. 2016;2(5):571–572. doi:10.1001/jamaoncol.2016.0043
Customize your JAMA Network experience by selecting one or more topics from the list below.